Thermo Fisher's first quarter 2026 results beat estimates, driven by a 12.6% surge in Life Sciences Solutions revenue.

Thermo Fisher Scientific reported first quarter revenue of $11.01 billion, a 6% increase year-over-year, and adjusted EPS of $5.44, up 6% from the prior year. These results surpassed analyst expectations for both revenue and earnings. Overall organic revenue growth for the company was 1%.

Key Highlights

• The key Life Sciences Solutions segment saw revenue grow 12.6% to $2.64 billion, significantly outpacing analyst expectations of 7.9% growth and signaling a strong recovery in bioprocessing demand.
• Total revenue of $11.01 billion and adjusted EPS of $5.44 beat consensus estimates of $10.83 billion and $5.21, respectively.
• The company continued its capital deployment strategy, repurchasing $3.0 billion of its stock and increasing its dividend by 10% during the quarter.